Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Breast Cancer

  Free Subscription

Articles published in Pathology

Retrieve available abstracts of 14 articles:
HTML format

Single Articles

    December 2020
  1. KAWASAKI T, Kaira K, Nakamura Y, Imai H, et al
    Re: INSM1 is a novel prognostic neuroedocrine marker for luminal B breast cancer.
    Pathology. 2020 Dec 29. pii: S0031-3025(20)31009.

  2. RAZVI H, Tsang JY, Tse GM
    Re: INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer: author reply.
    Pathology. 2020 Dec 28. pii: S0031-3025(20)31010.

    September 2020
  3. RAZVI H, Tsang JY, Poon IK, Chan SK, et al
    INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer.
    Pathology. 2020 Sep 17. pii: S0031-3025(20)30888.
    PubMed     Abstract available

    June 2020
  4. FUCHS TL, Pearson A, Pickett J, Diakos C, et al
    Why pathologists and oncologists should know about tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer: an Australian experience of 139 cases.
    Pathology. 2020 Jun 14. pii: S0031-3025(20)30822.
    PubMed     Abstract available

    April 2020
  5. MACNEIL JAB, Selegean S, Williams AS
    Metastatic lobular carcinoma presenting as retroperitoneal fibrosis: a rare presentation detected using post-mortem cytology.
    Pathology. 2020;52:387-390.

    February 2020
  6. RHODES A, Teoh KH, See MH, Ganesan K, et al
    Breast cancer hormone receptor testing in Asia: is it time to think again on expected positivity rates and methods of scoring?
    Pathology. 2020 Feb 24. pii: S0031-3025(20)30709.

  7. XU Z, Shen W, Pan A, Sun F, et al
    Decreased Nek9 expression correlates with aggressive behaviour and predicts unfavourable prognosis in breast cancer.
    Pathology. 2020 Feb 22. pii: S0031-3025(20)30458.
    PubMed     Abstract available

    June 2019
  8. LIEN HC, Lee YH, Juang YL, Lu YT, et al
    Fibrillin-1, a novel TGF-beta-induced factor, is preferentially expressed in metaplastic carcinoma with spindle sarcomatous metaplasia.
    Pathology. 2019;51:375-383.
    PubMed     Abstract available

    May 2019
  9. FARSHID G, Bilous M, Morey A, Fox S, et al
    ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia.
    Pathology. 2019 May 7. pii: S0031-3025(18)30615.
    PubMed     Abstract available

    April 2019
  10. WANG M, McLaren S, Jeyathevan R, Allanson BM, et al
    Laboratory validation studies in Ki-67 digital image analysis of breast carcinoma: a pathway to routine quality assurance.
    Pathology. 2019;51:246-252.
    PubMed     Abstract available

  11. ZABOROWSKI M, Pearson A, Sioson L, Gill AJ, et al
    Androgen receptor immunoexpression in triple-negative breast cancers: is it a prognostic factor?
    Pathology. 2019;51:327-329.

  12. DESSAUVAGIE BF, Thomas C, Robinson C, Harvey J, et al
    Digital evaluation of proliferative 'hotspots' of more than 16,000 cells negatively impacts Ki-67 assessment in breast carcinoma.
    Pathology. 2019;51:329-331.

    August 2018
    Spontaneous breast haematoma in a woman with Bernard-Soulier giant platelet disorder.
    Pathology. 2018;50:578-580.

    April 2018
  14. LIM JCT, Yeong JPS, Lim CJ, Ong CCH, et al
    An automated staining protocol for seven-colour immunofluorescence of human tissue sections for diagnostic and prognostic use.
    Pathology. 2018;50:333-341.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.